DUBLIN--(BUSINESS WIRE)--The "Artificial Intelligence for Drug Discovery in the Pharmaceutical Industry, 2020" report has been added to ResearchAndMarkets.com's offering.
Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16% in 2011 to almost 11% in 2018. Research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniques to address the understanding around targets and leads are inefficient. The increasing volume and veracity of clinical and research data compels traditional providers to leverage converging technologies such as artificial intelligence (AI), machine learning, natural language processing, and advanced analytics to shift from static to dynamic and adaptive data management practices.
The ecosystem for supporting this growth has matured: several technology start-ups and large commercial vendors have already started delivering the impact through their products and solutions catering to drug discovery. While the benefits over the next 2 to 3 years are expected to be achieved through improved drug pipelines and faster clinical approval of new molecules, beyond that companies that integrate AI solutions will see significant impact on efficiency, cost savings and commercial success depending on their business goals.
Analysis shows that the AI impact over the pharma value chain can more than double what is achievable using traditional analytics and capture between 2% and 3% of the industry revenue, amounting to more than $50 billion in potential annual impact. This report recognizes the participants that are at the forefront of developing and employing the tools. This is an industry-first benchmarking study that provides an introduction to the ecosystem and recognizes the pioneering companies.
This report reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the methodology. The document presents competitive profiles on each of the companies in the report based on their strengths, opportunities, and a small discussion on their positioning. The publisher analyzes hundreds of companies in the industry and benchmarks them across 10 criteria, where the leading companies in the industry are then positioned. Industry leaders on both the Growth and Innovation indices are recognized as best practice recipients.
Key Topics Covered:
Strategic Imperative and Growth Environment
- Strategic Imperative
- AI for Drug Discovery Market Segmentation
- Growth Environment
Companies to Action
- Acurastem, Inc.
- AI Therapeutics
- Biovista Inc.
- Cotinga Pharmaceuticals Inc.
- Evaxion Biotech
- Exscientia Ltd.
- Gritstone Oncology, Inc.
- Insilico Medicine
- Lantern Pharma, Inc.
- Recursion Pharmaceuticals
Next Steps: Leveraging to Empower Key Stakeholders
- Empowers The CEO's Growth Team
- Empowers Investors
- Empowers Customers
- Empowers the Board of Directors
- Benchmarking Future Growth Potential
For more information about this report visit https://www.researchandmarkets.com/r/2fiuqy